JP MORGAN/CALL/EDWARDS LIFESCIENCES/125/0.1/21.06.24

JP MORGAN/CALL/EDWARDS LIFESCIENCES/125/0.1/21.06.24 Stock

Warrant

DE000JL7JMY6

Market Closed - Börse Stuttgart 10:15:55 2024-05-23 am EDT
0.001 ^EUR	-.--%

3 months	-85.71%
6 months	-66.67%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart EDWARDS LIFESCIENCES CORPORATION

Chart JP MORGAN/CALL/EDWARDS LIFESCIENCES/125/0.1/21.06.24

Latest news about EDWARDS LIFESCIENCES CORPORATION

Five-Year Data Show Excellent Outcomes for Female and Small Annulus Patients With Edwards TAVR	Jun. 05	BU
Edwards Lifesciences Announces Results from Analysis of Data from Partner Trials Examining Outcomes of Transcatheter Aortic Valve Replacement Patients with Small Annulus	Jun. 05	CI
Transcript : Edwards Lifesciences Corporation Presents at Jefferies 2024 Global Healthcare Conference, Jun-05-2024 10:30 AM	Jun. 05
Transcript : Edwards Lifesciences Corporation Presents at The 44th Annual William Blair Growth Stock Conference, Jun-04-2024 12:00 PM	Jun. 04

More news

Static data

Product type	Plain-Vanilla-Warrants
Buy / Sell	CALL
Underlying	EDWARDS LIFESCIENCES CORPORATION
Issuer	J.P. Morgan
WKN	JL7JMY
ISIN	DE000JL7JMY6
Date issued	2023-07-13
Strike	125 $
Maturity	2024-06-21 (6 Days)
Parity	10 : 1
Emission price	0.22 €
Emission volume	N/A
Settlement	cash
Currency	EUR

Technical Indicators

Highest since issue	0.23 €
Lowest since issue	0.001 €
Spread	0.05 €
Spread %	98.04%

Company Profile

Edwards Lifesciences Corporation specializes in designing, manufacturing and marketing medical systems and devices for treating cardiovascular diseases. Net sales break down by family of products as follows: - heart valves and surgery products (67.9%); - hemodynamic monitoring systems (15.5%); - other (16.6%): balloon catheters, artificial implants, etc. Net sales are distributed geographically as follows: the United States (58.4%), Europe (22.2%), Japan (7.6%) and other (11.8%).

Sector

More about the company